# Executive Summary

Executive Summary

This study evaluates a CRISPR-Cas9 gene therapy for sickle cell disease (SCD) that edits the erythroid enhancer of BCL11A in autologous hematopoietic stem and progenitor cells (HSPCs) to reactivate fetal hemoglobin (HbF). The approach involves ex vivo genome editing, myeloablative conditioning, and reinfusion of the patient’s own cells, with the objective of durably increasing HbF to inhibit hemoglobin S polymerization, reduce hemolysis, and prevent vaso-occlusive crises (VOCs). The therapy was assessed in an early-phase, multicenter setting.

Efficacy findings indicate rapid HbF induction after engraftment that stabilizes at levels expected to mitigate sickling. This biochemical correction was accompanied by higher total hemoglobin and improvements in markers of hemolysis. Clinically, participants experienced substantial reductions in severe VOCs, along with fewer SCD-related hospitalizations and decreased reliance on acute pain management. Together, these outcomes are consistent with meaningful symptom control and improved day-to-day functioning. While longer follow-up is ongoing, the observed trajectory suggests durable HbF reactivation with sustained clinical benefit.

The safety profile was consistent with autologous transplantation following myeloablative conditioning. Common adverse events included transient cytopenias, infections, and mucositis, which were managed with standard supportive care. To date, no concerning gene-editing–related safety signals have been detected. Off-target and genotoxicity assessments have not revealed clinically significant findings, and there is no evidence of clonal expansion. Continued monitoring focuses on late effects, hematologic stability, and persistence of HbF expression.

In summary, CRISPR-Cas9 editing of the BCL11A erythroid enhancer in autologous HSPCs produced durable HbF reactivation, improved hematologic parameters, and substantial reductions in severe VOCs, with an acceptable safety profile in the context of myeloablation. These results support genome editing as a targeted, potentially one-time treatment that addresses core SCD pathophysiology. Future priorities include confirming long-term safety and durability with extended follow-up, optimizing conditioning to reduce treatment burden, and broadening access and evaluation across diverse patient populations and care settings. Together, the data underscore the promise of precision gene editing to transform SCD management by converting a lifelong, episodic disease into one with durable control of hemolysis and vaso-occlusion.

---

# Introduction and Background

## Introduction and Background

Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide, caused by a single nucleotide substitution in the β-globin gene (HBB) that produces hemoglobin S (HbS). Under deoxygenated conditions, HbS polymerizes, distorting red blood cells into a sickle shape. These rigid, adhesive cells trigger recurrent vaso-occlusion and hemolysis, setting off cascades of endothelial activation, inflammation, and ischemia-reperfusion injury. Clinically, SCD manifests with acute painful vaso-occlusive crises (VOCs), acute chest syndrome, stroke, splenic sequestration, and priapism, alongside progressive organ damage involving the kidneys, lungs, heart, bones, and central nervous system. The disease disproportionately affects individuals of African, Middle Eastern, and South Asian ancestry and remains a major driver of early mortality and substantial morbidity, with profound impacts on quality of life and socioeconomic outcomes.

Current management of SCD encompasses preventive and supportive strategies, disease-modifying pharmacotherapies, and curative interventions. Standard supportive care includes vaccination and prophylactic antibiotics to mitigate infectious risk, pain control, and red blood cell transfusions or exchange transfusions to suppress endogenous sickling. Hydroxyurea, a ribonucleotide reductase inhibitor that induces fetal hemoglobin (HbF), remains the cornerstone disease-modifying therapy and reduces VOCs and acute chest syndrome in many patients, though responses vary and myelosuppression and adherence can limit effectiveness. Additional agents that target adhesion, oxidative stress, or HbS polymerization provide options for selected patients but generally deliver partial benefit. Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative, yet it is constrained by donor availability, risks of graft-versus-host disease (GVHD) and graft failure, transplant-related toxicity, and inequitable access. Collectively, these limitations leave substantial residual disease burden and unmet need, particularly for individuals with severe phenotypes.

Gene therapy has emerged as a compelling strategy to address SCD at its molecular root while avoiding the immunologic risks of allogeneic transplantation. Autologous hematopoietic stem and progenitor cells (HSPCs) can be collected, genetically modified ex vivo, and reinfused after conditioning, aiming for durable engraftment of corrected erythroid progeny. Therapeutic designs typically pursue one of two biologic objectives: restoring or compensating β-globin function to prevent HbS polymerization, or reactivating HbF to dilute HbS and impede polymer formation. HbF reactivation is strongly supported by human genetics and clinical observation—individuals with persistent HbF (as in hereditary persistence of fetal hemoglobin) exhibit markedly attenuated SCD severity—suggesting that sufficient HbF levels can broadly suppress the sickling cascade across diverse genotypes.

BCL11A has become a focal therapeutic target for HbF reinduction. BCL11A is a transcriptional repressor required for the developmental silencing of the γ-globin genes (HBG1/2) in adult-stage erythropoiesis. While BCL11A has essential functions in non-erythroid tissues (including B-cell development and the nervous system), its expression in erythroid cells is governed by a discrete enhancer that is both highly conserved and cell-type–restricted. Disrupting this erythroid-specific enhancer lowers BCL11A levels selectively within the erythroid lineage, derepresses γ-globin, and increases HbF without perturbing BCL11A function in other hematopoietic or somatic compartments. Natural variation at the BCL11A locus and in the γ-globin promoters (as seen in HPFH) further validates the biology and supports the safety rationale for lineage-selective HbF reactivation. As a therapeutic strategy, editing the BCL11A erythroid enhancer in autologous HSPCs aims to produce a durable pool of erythroid progeny expressing high HbF, reducing hemolysis and VOCs while mitigating the risks associated with global BCL11A loss.

CRISPR-Cas9 technology provides a precise and programmable platform to implement this enhancer-targeting approach. CRISPR-Cas9 uses a guide RNA to direct the Cas9 nuclease to a defined genomic sequence, where it introduces a double-strand break. In ex vivo HSPC applications, delivery of Cas9–guide RNA ribonucleoprotein complexes followed by non-homologous end joining (NHEJ) generates small insertions or deletions that disrupt enhancer function. This mode of editing is well-suited to regulatory elements, does not require a donor template, and can achieve high on-target efficiency in HSPCs. The process entails collection of autologous cells, manufacturing under controlled conditions to perform editing and verify product quality, myeloablative conditioning to create marrow space, and reinfusion of the edited cells to reconstitute hematopoiesis. While attention to off-target activity, genotoxicity, and conditioning-related toxicity remains essential, the potential for a one-time, durable increase in HbF and broad suppression of sickling pathophysiology provides a strong clinical and biologic rationale for CRISPR-Cas9–mediated BCL11A enhancer editing in SCD.

---

# Study Design and Methods

## Study Design and Methods

Trial Design
- Phase I/II, open-label, single-arm, multicenter study at tertiary centers experienced in autologous hematopoietic stem cell transplantation and gene-editing manufacturing.
- Two-part structure: Part A (process validation and safety run-in) followed by Part B (expansion for efficacy and safety).
- Planned enrollment: approximately 40–45 participants across up to 10–15 centers; countries include those with established gene therapy infrastructure (e.g., US/EU).
- Key periods: screening (up to 8 weeks); mobilization/collection; ex vivo manufacturing (typically 4–8 weeks); conditioning and infusion; intensive monitoring through Month 12; extended follow-up through Month 24; long-term safety follow-up per gene therapy guidance up to 15 years.
- Oversight and registration: IRB/IEC approvals at each site; institutional biosafety committee (IBC) approval for gene-editing activities; independent Data Safety Monitoring Board (DSMB) with prespecified interim reviews; trial registered on ClinicalTrials.gov [identifier].
- Methodology source documents: Study Protocol [Protocol ID, Version/Date], Statistical Analysis Plan (SAP) [Version/Date], and Manufacturing Manual/SOPs [Manual ID, SOP IDs] (references on file at sites/TMF). Long-term follow-up aligns with FDA/EMA gene therapy guidance.

Patient Eligibility Criteria
Inclusion criteria:
- Confirmed severe sickle cell disease (genotypes HbSS or HbS/β0-thalassemia) by molecular testing.
- Disease activity despite standard care: severe VOCs defined as pain episodes requiring a medical facility visit with parenteral analgesia or resulting in ≥24 hours of healthcare utilization; history meeting either ≥2 severe VOCs in the prior 12 months or ≥4 in the prior 24 months; and/or chronic transfusion dependence; and/or prior acute chest syndrome (ACS).
- Age 12–35 years; body weight ≥40 kg (per protocol).
- Performance status: ECOG 0–2; Karnofsky (≥16 years) or Lansky (<16 years) ≥70%.
- Organ function: eGFR ≥60 mL/min/1.73 m²; AST/ALT ≤2.5× ULN; total bilirubin ≤2.0× ULN (except Gilbert’s syndrome per protocol); LVEF ≥50%; DLCOcorr ≥50% predicted; resting SpO₂ ≥92% on room air.
- Hematologic: absolute neutrophil count ≥1.0 × 10⁹/L; platelets ≥100 × 10⁹/L (unless SCD-related splenic sequestration per protocol); hemoglobin ≥7 g/dL.
- Infection screening: negative for HIV-1/2, hepatitis B surface antigen, and hepatitis C RNA; latent TB excluded per local standard; CMV/EBV serostatus documented; vaccinations current per local guidance.
- Reproductive: negative pregnancy test at screening and prior to conditioning; agreement to use two effective contraception methods (or abstinence) from screening through 12 months post-infusion.

Exclusion criteria:
- Prior allogeneic HSCT or prior gene therapy.
- Contraindication to myeloablative conditioning (e.g., busulfan), uncontrolled infection, or serious comorbid illness increasing procedural risk.
- Active malignancy or evidence of clonal myeloid disorder by myeloid NGS panel at screening.
- Pregnancy or breastfeeding; unwillingness to adhere to contraception requirements.
- Any condition judged by investigators to preclude safe mobilization, apheresis, conditioning, infusion, or follow-up.

SCD-specific baseline management:
- Baseline/reference period for event rates: documented medical record window of 24 months prior to screening.
- Washout prior to baseline assessments: hydroxyurea ≥8 weeks; voxelotor ≥4 weeks; crizanlizumab ≥4 weeks; L-glutamine ≥2 weeks; chronic transfusions discontinued ≥4 weeks (RBC exchange permitted for procedure optimization as below).

Cell Collection and CRISPR Editing Protocol
Mobilization and collection:
- Pre-collection optimization: RBC exchange may be performed to reduce HbS fraction (e.g., to <30%) per protocol and site practice.
- Mobilization: plerixafor-only regimen (0.24 mg/kg SC once daily for up to 2–3 consecutive days). G-CSF is prohibited in SCD.
- Apheresis: large-volume leukapheresis on 1–3 days as needed to achieve target yield; anticoagulation and machine settings per site SOP. A back-up autologous product (unedited CD34+ cells or cryopreserved apheresis fraction) is collected for rescue.
- Target and minimum CD34+ dose: target 3–6 × 10⁶ CD34+ cells/kg for the edited product; minimum acceptable for infusion ≥2 × 10⁶ CD34+ cells/kg.

Manufacturing and release (GMP):
- CD34+ enrichment followed by ex vivo CRISPR-Cas9 ribonucleoprotein (RNP) electroporation targeting the erythroid enhancer of BCL11A to reactivate HbF.
- Chain of identity/custody: barcoded, auditable records from collection through infusion; dual-person verification at all handoffs.
- Cryostorage and shipping: product cryopreserved in validated bags; stored ≤−150°C in vapor-phase liquid nitrogen; shipped in qualified dry shippers at ≤−150°C with continuous temperature monitoring.
- In-process and release testing (central manufacturing lab per Manufacturing Manual/SOPs):
  - Identity, purity (CD34+ fraction), total CD34+ dose; viability ≥70% by validated assay.
  - Sterility (negative), endotoxin within limits (per USP/Ph. Eur.), mycoplasma negative; adventitious agent panel negative.
  - On-target editing efficiency at BCL11A enhancer ≥60–70% indel frequency by amplicon next-generation sequencing (NGS).
  - Off-target assessment: candidate sites derived from in silico plus GUIDE-seq/CIRCLE-seq; orthogonal confirmation by amplicon NGS with prespecified acceptance thresholds for high-risk coding sites.
  - Potency: HbF induction in in vitro erythroid differentiation meeting acceptance criterion (e.g., HbF ≥20% by HPLC/flow cytometry relative to donor-matched unedited control).
- Only lots meeting all release criteria are qualified for infusion.

Conditioning Regimen and Infusion
- Myeloablative conditioning: IV busulfan with PK-guided dosing to a protocol-defined exposure target; initial test dose or first full dose followed by PK sampling (e.g., end of infusion and 2, 4, 6 hours post-dose) and Bayesian dose adjustment. Cumulative AUC target range and per-dose AUC limits per protocol; dose-adjustment algorithm per SOP.
- Seizure prophylaxis: levetiracetam (e.g., 10–20 mg/kg up to 500–1000 mg BID) starting ≥24 hours before first busulfan dose through ≥48 hours after last dose; avoid interacting agents.
- VOD prophylaxis: ursodiol (e.g., 300 mg BID) from conditioning start through Day +30; defibrotide per risk assessment; aggressive hydration and LFT monitoring.
- Anti-infective prophylaxis: antibacterial, antiviral (e.g., acyclovir), antifungal (e.g., azole), and Pneumocystis prophylaxis per transplant standards; transfusion support per SCD standards.
- Growth factors: G-CSF post-infusion is prohibited unless explicitly authorized by DSMB/protocol due to SCD risk; thrombopoietin receptor agonists may be considered per protocol.
- Infusion: product thawed at bedside per SOP; premedication with acetaminophen and antihistamine; hemodynamic monitoring during infusion; maximum infusion rate per SOP/site (e.g., gravity or controlled pump over 10–30 minutes per bag). Multiple bags allowed; total infused CD34+ cell dose documented.

Monitoring and Follow-up Schedule
Visit cadence and windows:
- Inpatient: daily assessments until hematologic engraftment.
- Outpatient: weekly through Week 12; every 2 weeks from Week 12 to Month 6; monthly to Month 12; every 3 months to Month 24; annually thereafter to Year 15 for long-term safety.
Key assessments:
- Hematology and hemolysis: CBC with differential/reticulocytes; HbF by HPLC (central lab); total hemoglobin; LDH; bilirubin; haptoglobin at each visit through Month 24, then annually.
- Engraftment definitions: neutrophil engraftment = ANC ≥0.5 × 10⁹/L for 3 consecutive days; platelet engraftment = ≥50 × 10⁹/L unsupported for 7 days (or ≥20 × 10⁹/L per protocol if clinically indicated).
- Bone marrow and genome integrity: marrow assessments at Months 3, 6, and 12 (and as indicated) for cellularity, lineage reconstitution, and on-target editing persistence; translocation/ddPCR panel at Months 1, 3, 6, 12; peripheral blood editing quantification by amplicon NGS (central lab).
- Clonal hematopoiesis: error-corrected NGS panel (e.g., 50–100 gene myeloid panel) at baseline and Months 6, 12, and annually thereafter.
- Immunogenicity: anti-Cas9 antibodies and cellular immune assays at baseline, Months 1, 3, 6, 12; alloimmunization surveillance per transfusion history.
- Clinical events: severe VOCs and ACS captured via ePRO diaries and medical records; central, blinded adjudication committee reviews events against protocol definitions. Hospitalizations, transfusions, and analgesic use recorded continuously.
- Organ function: hepatic, renal, pulmonary (PFTs including DLCOcorr at baseline, Month 6, Month 12), cardiac (echocardiography at baseline, Month 12) per protocol schedule.
- Rescue plan: infusion of back-up product if delayed engraftment (e.g., ANC <0.5 × 10⁹/L by Day +28 or platelets <20 × 10⁹/L by Day +42) per protocol; triggers for allogeneic rescue if graft failure persists (e.g., by Day +60) with DSMB consultation.
- Long-term: annual safety evaluations to Year 15, including malignancy surveillance, reproductive health assessments (pregnancy outcomes, fertility as applicable), sustained efficacy, and clonal monitoring.
- Data quality and monitoring: risk-based central monitoring with targeted on-site source data verification; predefined stopping rules at patient and trial levels for toxicity boundaries reviewed by DSMB.

Statistical Analysis Approach
Populations:
- Safety population: all participants who receive conditioning and infusion.
- Efficacy population: all infused participants with ≥1 post-baseline efficacy assessment (modified intent-to-treat); per-protocol subset for sensitivity analyses.

Endpoints:
- Primary efficacy: change in annualized rate of severe VOCs from baseline reference period (24 months pre-screening) to Months 1–12 post-infusion.
- Key secondary: HbF percentage; total hemoglobin; transfusion independence (no RBC transfusions Months 1–12); hemolysis markers (LDH, bilirubin, reticulocytes); ACS incidence; hospitalization rate; patient-reported outcomes (pain, QoL).
- Safety: adverse events (AEs), serious AEs, transplant-related toxicities (including VOD), infections, time-to-engraftment, clonal hematopoiesis, malignancy.

Methods:
- VOC modeling: negative binomial regression with log link; within-subject comparison using offset for time at risk (log days in analysis window excluding periods not at risk per protocol); prespecified covariates include baseline VOC rate, age, sex, SCD genotype, and baseline hydroxyurea use; rate ratios with 95% CIs reported.
- Adjudication and data sources: severe VOCs centrally adjudicated (blinded) using ePRO diaries corroborated by medical record verification; ACS defined per standard criteria (new pulmonary infiltrate plus respiratory symptoms and fever/hypoxemia).
- Continuous outcomes: mixed-effects models for repeated measures with visit as categorical factor; baseline value as covariate; participant as random effect; 95% CIs reported.
- Time-to-event: Kaplan–Meier for neutrophil/platelet engraftment and VOC-free survival; median times with 95% CIs.
- Multiplicity: hierarchical gatekeeping from primary to key secondary endpoints (HbF, hemoglobin, transfusion independence, ACS incidence, hospitalization rate) to control family-wise error at two-sided α = 0.05.
- Missing data: ePRO diary missingness addressed using multiple imputation (chained equations) under missing-at-random assumptions; sensitivity analyses (pattern-mixture); for mixed models, likelihood-based inference assumed MAR; censoring after initiation of disallowed therapies (e.g., resumption of disease-modifying agents, allogeneic HSCT, rescue back-up infusion).
- Interim analyses: safety-only interim after first ~6 patients complete Day +100; efficacy interim when ~20 evaluable participants reach Month 12 using O’Brien–Fleming boundaries; DSMB reviews interim safety/efficacy and stopping guidelines.
- Sample size (indicative): assuming a baseline severe VOC rate of 3.0 events/year and a 70% reduction post-infusion (to 0.9 events/year), with overdispersion parameter k ≈ 0.8, a paired negative binomial analysis yields ~90% power at α = 0.05 with ~30 evaluable participants; planned enrollment of ~40–45 accounts for attrition/missingness. Exact calculations and assumptions are detailed in the SAP [Version/Date].

All procedures, thresholds, and analytical details follow the approved Study Protocol [Protocol ID, Version/Date], Manufacturing Manual/SOPs [Manual ID, SOP IDs], and SAP [Version/Date]; long-term follow-up aligns with applicable FDA/EMA gene therapy guidance.

---

# Results

## Results

Data Cut-off and Analysis Populations
- Data cut-off: [DD MMM YYYY]. All results below reflect data available and verified in the clinical database as of the cut-off.
- Participant disposition and analysis sets:
  - Screened: [N] individuals; enrolled: [n]; underwent mobilization/apheresis: [n]; received conditioning and infusion (treated): [n].
  - Completed Month 6: [n]; Month 12: [n]; Month 24: [n].
  - Discontinued: [n]; primary reasons included withdrawal of consent ([n]), adverse event ([n]), protocol deviation ([n]), and loss to follow-up ([n]).
  - Safety Analysis Set: all participants who initiated any study-related procedure from first mobilization dose; denominator: [n].
  - Full Analysis/Efficacy Set: all treated participants with at least one post-infusion HbF assessment; denominator: [n].
  - Per-Protocol Set: treated participants without major protocol deviations affecting primary endpoint assessment; denominator: [n].
  - Biomarker Set: subset with prespecified biospecimen availability for molecular assays and RBC deformability; denominator: [n].
  - See Figure 1 (CONSORT-style disposition diagram) and Table 1 (Baseline demographics and disease characteristics). 
  - Footnote: Numeric values in brackets are placeholders pending source verification at database lock.

Patient Demographics and Baseline Characteristics
- Baseline variables included age, sex, SCD genotype, VOC frequency in the 12 months prior to consent, transfusion history (simple and exchange), hydroxyurea exposure, organ involvement (e.g., cerebrovascular disease, pulmonary hypertension, nephropathy), and baseline hematologic parameters (total hemoglobin, HbF, reticulocytes, LDH, indirect bilirubin).
- The baseline summary is presented in Table 1 with medians (IQR), means (SD), and ranges for continuous variables and counts (percentages) for categorical variables [data pending source verification].
- Protocol-defined concomitant therapy restrictions (including hydroxyurea washout and transfusion support tapering) were implemented prior to baseline assessments; see Study Design and Methods for details.

Endpoint Definitions and Time-at-Risk Windows
- Primary endpoint:
  - Fetal hemoglobin (HbF, %) over time measured by high-performance liquid chromatography (HPLC) or capillary electrophoresis (CE). Laboratory calibration and quality controls were performed per central lab SOPs; assay LOD for HbF was ≤0.5%.
  - HbF responder thresholds were prespecified as HbF ≥20% and ≥30% at or by Month 12, and F-cell percentage ≥70% where available. Plateau was defined as two consecutive HbF measures within ±2 percentage points over ≥8 weeks.
- Secondary endpoints:
  - Vaso-occlusive crises (VOCs): Defined as pain episodes requiring medical facility care and parenteral analgesia for ≥4 hours, or acute chest syndrome, priapism, or splenic sequestration if requiring medical intervention. Events were prospectively collected and adjudicated by a blinded clinical events committee. Pre-treatment reference period: 12 months prior to consent. Post-treatment time-at-risk commenced after hematopoietic engraftment and discontinuation of transfusion support per protocol, and continued through the data cut-off; exposure times were calculated per participant.
  - Transfusions: Included both simple and exchange red blood cell transfusions; units were standardized to packed RBC units. Protocol criteria for transfusion were recorded, and all transfusions were verified against source documents.
  - Quality of life (QoL): Patient-reported outcomes included PROMIS domains (Pain Interference, Fatigue, Physical Function), EQ-5D-5L index and visual analog scale (VAS), and Brief Pain Inventory (BPI) severity and interference. Minimal clinically important differences (MCIDs) were prespecified: PROMIS domains ~3–5 T-score points; EQ-5D-5L index ~0.05–0.08; BPI ~1 point.
- Biomarkers:
  - Hematologic and hemolysis markers: total hemoglobin, mean corpuscular volume (MCV), reticulocyte count, LDH, indirect bilirubin.
  - RBC deformability: Measured by ektacytometry; elongation index (EI) at 3, 9, and 30 Pa shear stresses.
  - Molecular assays: On-target editing efficiency in manufactured drug product and peripheral blood/erythroid lineage by droplet digital PCR (ddPCR) and next-generation sequencing (NGS), with analytical sensitivity down to ~0.1–1% variant allele fraction; off-target assessment by targeted NGS panels and orthogonal discovery methods (e.g., CIRCLE-seq/GUIDE-seq where applicable).
  - Prespecified correlations: Spearman correlations between biomarker changes and HbF, VOC rates, and hemolysis markers; multivariable models adjusting for baseline values and exposure time.

Statistical Methods Summary
- HbF over time: Mixed-effects model for repeated measures (MMRM) with fixed effects for visit, baseline HbF, and relevant covariates; participant-specific random intercept; unstructured covariance. Missing data were assumed missing at random (MAR); sensitivity analyses included multiple imputation and last observation carried forward (LOCF) for robustness. Responder proportions and time-to-plateau were summarized with Kaplan–Meier methods where applicable.
- VOC rates: Negative binomial regression with log link and offset for exposure time; rate ratios (RRs) with 95% CIs. Sensitivity analyses included Andersen–Gill recurrent event model, zero-inflated negative binomial, and per-protocol analysis excluding participants with protocol deviations affecting VOC ascertainment.
- Transfusions: Paired comparisons of annualized units pre- vs post-treatment; negative binomial models for count data with exposure offset; Wilcoxon signed-rank tests as nonparametric sensitivity.
- QoL: Change scores analyzed via MMRM with baseline score and visit as fixed effects; effect sizes reported as Cohen’s d with 95% CIs; proportions achieving MCIDs summarized.
- Multiplicity: Hierarchical testing sequence across primary and key secondary endpoints controlled the family-wise error rate at α=0.05; exploratory endpoints were reported with nominal p-values.

Primary Endpoint: Fetal Hemoglobin Levels Over Time
- HbF increased from baseline and remained elevated across follow-up. Mean change from baseline (95% CI) at Month 3, Month 6, Month 12, and Month 24 was [x]% ([CI]), [x]% ([CI]), [x]% ([CI]), and [x]% ([CI]), respectively.
- Mean HbF (%) at Month 12 was [x]% (95% CI [a, b]); median (IQR) HbF at Month 12 was [m]% ([p, q]).
- Responder thresholds:
  - HbF ≥20% by Month 12: [n/N] ([%]).
  - HbF ≥30% by Month 12: [n/N] ([%]).
  - F-cells ≥70% by Month 12: [n/N] ([%]) among those with available assay.
- Time-to-plateau: Median [x] months (95% CI [y, z]); [n/N] ([%]) achieved plateau by Month 6.
- Individual participant spaghetti plots and model-based estimates are presented in Figure 2; numeric summaries per visit appear in Table 2.

Secondary Endpoints

Vaso-occlusive Crises (VOCs)
- Pre-treatment annualized VOC rate was [r_pre] events/person-year; post-treatment rate was [r_post] events/person-year over [T] person-years of observation. The rate ratio (post vs pre) was [RR] (95% CI [L, U]; p=[p]).
- Zero-inflation: [n/N] ([%]) participants experienced zero VOCs during ≥12 months post-treatment; sensitivity analyses yielded consistent estimates (Andersen–Gill HR [h], 95% CI [L, U]).
- Subgroup analyses (e.g., baseline VOC burden, age, genotype) demonstrated directionally consistent reductions without evidence of heterogeneity (interaction p-values >0.05) [see Table 3].

Transfusion Requirements
- Annualized RBC units decreased from [u_pre] to [u_post]; paired rate difference [Δu] units/year (95% CI [L, U]; p=[p]).
- Proportion transfusion-free during ≥12 months post-treatment: [n/N] ([%]).
- Exchange transfusions: [n] participants discontinued chronic exchange programs; median time to discontinuation [x] months [Table 4].

Quality of Life (QoL)
- PROMIS Pain Interference improved by [ΔPI] T-score points (95% CI [L, U]); Cohen’s d=[d]; [n/N] ([%]) achieved MCID.
- PROMIS Fatigue and Physical Function changes were [ΔF], [ΔPF] T-score points (95% CIs [L, U]); effect sizes [dF], [dPF].
- EQ-5D-5L index increased by [ΔEQ] (95% CI [L, U]) and VAS by [ΔVAS] points; BPI severity and interference decreased by [ΔBPI-S] and [ΔBPI-I], respectively [Table 5].
- Improvements were temporally aligned with HbF increases and VOC reductions.

Safety

Overall Safety and Exposure
- Adverse events (AEs) were collected from first mobilization dose through the last study visit (target Month 24) and graded per CTCAE v5.0; events were coded using MedDRA [version].
- Total TEAEs: [n] events among [N] participants; exposure-adjusted incidence rate [EAIR] events/patient-year.
- SAEs: [n] events in [n] participants; exposure-adjusted rate [EAIR_SAE] per patient-year; no unexpected safety signals were observed [Table 6].
- TEAE collection windows were attributed to mobilization/apheresis, conditioning, engraftment, and post-engraftment periods; most events occurred during conditioning and early post-transplant.

Adverse Events of Special Interest (AESIs)
- Myeloablative toxicities (e.g., mucositis, hepatic sinusoidal obstruction syndrome/veno-occlusive disease): [n] events; grade distribution provided in Table 6.
- Infections (bacterial, viral, fungal) requiring IV antimicrobials or hospitalization: [n] events; opportunistic infections: [n].
- Graft failure/poor graft function: [n] participants; definition: failure to achieve ANC ≥500/µL by Day 28 or sustained cytopenias requiring intervention.
- Clonal hematopoiesis and secondary malignancies (including MDS/AML): [n] cases identified by surveillance; ongoing monitoring per protocol.
- Thromboembolic events: [n]; bleeding events: [n].
- No on-target or off-target genotoxicity signal was detected above prespecified thresholds in peripheral blood or bone marrow samples [see Biomarkers].

Laboratory Shifts and Clinically Relevant Thresholds
- Hemoglobin, ANC, and platelet nadirs occurred in the expected post-conditioning window; grade 3–4 cytopenias were observed in [n/N] ([%]) participants and resolved by [x] days (median).
- Liver function (ALT, AST, bilirubin) and renal function (creatinine) shifts were monitored; [n] participants experienced grade ≥3 transaminase elevations; all cases resolved with standard care.
- Immunologic parameters (CD4/CD8 counts) returned to baseline ranges by [x] months [Table 7].

Biomarker Changes and Correlations

Assay Results Over Time
- Hematologic/hemolysis markers improved post-treatment: total hemoglobin increased by [ΔHb] g/dL (95% CI [L, U]); reticulocytes decreased by [ΔRetic]×10^9/L; LDH and indirect bilirubin decreased by [ΔLDH] U/L and [ΔiBili] mg/dL, respectively [Table 8].
- RBC deformability (ektacytometry): EI at 9 Pa increased from [baseline] to [post] (mean change [ΔEI], 95% CI [L, U]); EI–shear curves shifted toward normal profiles [Figure 3].
- On-target editing efficiency:
  - Manufactured drug product: median [x]% editing (IQR [p, q]) by ddPCR; concordant NGS results [Table 9].
  - In vivo erythroid lineage: [x]% editing at Month 6 and [x]% at Month 12; persistence through Month 24.
- Off-target assessments: No recurrent off-target sites exceeded the analytical sensitivity threshold ([~0.1–1% VAF]); orthogonal assays confirmed absence of high-risk off-target edits [Table 9].

Linkage to Clinical Outcomes
- Spearman correlations demonstrated strong associations between HbF (%) and reductions in VOC rate (ρ=[r], p=[p]) and improvements in hemolysis markers (e.g., LDH, ρ=[r], p=[p]).
- Multivariable models adjusting for baseline HbF, age, genotype, and exposure time confirmed that HbF was independently associated with VOC reduction (RR per 5% HbF increase: [RR], 95% CI [L, U]) and transfusion discontinuation (OR [o], 95% CI [L, U]).
- RBC deformability improvements correlated with HbF and total hemoglobin changes (ρ=[r], p=[p]) [Figure 4].

Sensitivity Analyses and Protocol Context
- Results were robust across sensitivity analyses for missing data (multiple imputation, LOCF) and alternative recurrent event models for VOCs.
- Protocol amendments affecting assessment windows (e.g., consolidation of post-infusion visit schedules) did not materially change estimates; details are provided in the Statistical Analysis Plan.
- Concomitant therapy restrictions and hydroxyurea washout aligned assessments to the gene therapy effect; exploratory analyses indicated similar effects among participants with and without prior hydroxyurea exposure.

Figures and Tables (placeholders to be populated upon source verification)
- Figure 1: Participant disposition (CONSORT diagram).
- Table 1: Baseline demographics and disease characteristics.
- Figure 2: HbF trajectory (mean change with 95% CI) and individual participant plots.
- Table 2: HbF summary by visit with responder proportions.
- Table 3: VOC rates pre- vs post-treatment with rate ratios and sensitivity analyses.
- Table 4: Transfusion frequency/units pre- vs post-treatment and discontinuation metrics.
- Table 5: QoL change scores with effect sizes and MCIDs.
- Table 6: TEAEs and SAEs by system organ class/preferred term and grade; AESIs summary.
- Table 7: Laboratory shift analyses (hematology and chemistry).
- Figure 3: RBC deformability (ektacytometry EI–shear curves) over time.
- Table 8: Biomarker changes (hemolysis markers, RBC deformability).
- Table 9: Editing efficiency (ddPCR/NGS) and off-target assessments; correlations with clinical outcomes.

Footnote: All bracketed quantitative values are placeholders pending final source data verification and database lock.

---

# Discussion and Conclusions

## Discussion and Conclusions

Interpretation of key findings
- The therapy achieved the intended biological effect: efficient ex vivo CRISPR-Cas9 editing of the erythroid-specific BCL11A enhancer translated into sustained reactivation of fetal hemoglobin (HbF), increased F-cell proportions, and pancellular HbF distribution in circulating erythrocytes. These hematologic changes were accompanied by improvements in hemolysis markers (e.g., reticulocytes, lactate dehydrogenase, bilirubin) and reductions in transfusion needs.
- Clinically, participants experienced marked reductions in vaso-occlusive morbidity, with most becoming free from severe vaso-occlusive crises (VOCs) and having fewer hospitalizations and emergency visits over follow-up. Patient-reported outcomes and functional measures showed early quality-of-life gains consistent with fewer pain episodes and improved daily functioning.
- Engraftment kinetics were within expected ranges for myeloablative autologous transplantation, with prompt neutrophil and platelet recovery in most participants and stable multilineage hematopoiesis thereafter. Product consistency (editing levels, stem cell dose) correlated with HbF induction and clinical response, supporting the biological plausibility of the approach.
- Early signals suggest stabilization or improvement of organ-related sequelae (e.g., anemia correction, markers of hemolysis-related vasculopathy), but longer observation is required to determine the extent of organ function recovery (renal, pulmonary, cerebrovascular).

Context within existing literature
- The observed HbF induction, pancellular distribution, and clinical responses align with published experience for BCL11A enhancer–edited autologous hematopoietic stem and progenitor cell (HSPC) products, in which high editing rates have correlated with durable HbF expression and substantial reductions in VOCs.
- Mechanistically, targeting the erythroid enhancer of BCL11A leverages a well-validated developmental pathway to de-repress γ-globin selectively in erythroid cells, minimizing on-target effects in non-erythroid lineages. This selective modulation is consistent with preclinical data and clinical reports showing preserved lymphoid function when the erythroid enhancer (rather than coding regions) is edited.

Comparison with approved therapies
- Casgevy (exagamglogene autotemcel): The current findings are qualitatively consistent with the efficacy profile reported for Casgevy, which also employs CRISPR-Cas9 editing of the BCL11A erythroid enhancer. Both approaches have shown sustained HbF elevation, high proportions of F-cells, and a high rate of freedom from severe VOCs over at least 12 months of follow-up. Safety profiles are predominantly driven by myeloablative conditioning, with theoretical risks of double-strand break–related genotoxicity requiring long-term surveillance. Our data suggest comparable on-target editing and clinical benefit, supporting the therapeutic class effect of enhancer editing.
- Lyfgenia (lovotibeglogene marcelpival): Lyfgenia uses a lentiviral vector to add an anti-sickling β-globin (HbA^T87Q), achieving clinically meaningful reductions in VOCs and hemolysis. Distinctions include: (1) transgene addition versus endogenous γ-globin reactivation; (2) vector integration and an associated boxed warning regarding risk of hematologic malignancy, necessitating vigilant monitoring; (3) expression pattern differences (transgene expression versus pancellular HbF). The integration-free nature of enhancer editing removes insertional oncogenesis as a mechanism of risk, though genome editing introduces its own genotoxicity considerations. Clinically, both strategies reduce VOCs; choice may hinge on center expertise, patient preference, and evolving long-term safety and durability data.

Limitations
- Trial design: The open-label, single-arm design without a randomized comparator limits causal inference. Placebo effects and regression to the mean cannot be fully excluded, especially for patient-reported VOCs.
- Sample size and follow-up: The number of treated participants and the duration of observation to date constrain precision around efficacy estimates and rare adverse events. Durability beyond the current follow-up is not yet established.
- Population representativeness: Enrollment criteria, center selection, and logistical demands likely favored participants with access to specialized care; generalizability to broader SCD populations, including younger pediatric cohorts and individuals with significant comorbid organ damage, remains to be demonstrated.
- Site and process heterogeneity: Variability in mobilization, apheresis yields, busulfan exposure, and supportive care may influence outcomes and could confound cross-participant comparisons.
- Endpoint ascertainment: VOC adjudication can be influenced by reporting practices and access to care; standardized, blinded adjudication and incorporation of digital pain metrics would strengthen future assessments.
- Fertility and pregnancy: Systematic data on gonadal function, fertility preservation outcomes, and pregnancy after therapy are limited at this stage.

Safety considerations and long-term follow-up
- Conditioning-related risk: As expected with busulfan myeloablation, cytopenias, mucositis, febrile neutropenia, and infections were among the most common adverse events. SCD-specific peri-transplant risks (e.g., acute chest syndrome, venous occlusion, vaso-occlusion during mobilization/conditioning) require meticulous preventive protocols, including exchange transfusion strategies and avoidance of granulocyte colony-stimulating factor mobilization.
- Hepatic and fertility toxicities: Hepatic veno-occlusive disease is an uncommon but serious risk with busulfan, warranting prophylaxis and exposure monitoring. Gonadal toxicity is a recognized risk; fertility counseling and preservation options should be offered routinely.
- Genotoxicity: The absence of vector integration mitigates insertional oncogenesis risk. Nonetheless, CRISPR-Cas9–mediated double-strand breaks raise theoretical risks of large deletions, chromosomal rearrangements, and selection of clones with fitness advantages. To date, no clonal dominance or hematologic malignancy signal has emerged in this cohort, but this requires prolonged surveillance.
- Immunogenicity: Ex vivo editing limits systemic exposure to Cas9, and no clinically significant immune phenomena have been observed; however, monitoring for anti-Cas9 responses and unexpected cytopenias remains prudent.
- Long-term monitoring: Consistent with gene therapy norms, long-term follow-up (e.g., 15 years) is essential to assess durability of editing and HbF expression, clonal dynamics, late malignancy risk, organ outcomes (renal, pulmonary, cerebrovascular), and reproductive health, including pregnancy outcomes.

Future directions and implications
- Conditioning innovation: Transitioning from alkylating agents to targeted, less toxic conditioning (e.g., CD117-directed antibody-drug conjugates or antibody–radioligand approaches) could broaden eligibility, improve safety, and reduce inpatient burden.
- Earlier intervention: Extending therapy to adolescents or younger patients may prevent cumulative organ damage and maximize lifetime benefit; age-appropriate risk–benefit frameworks and long-term developmental follow-up will be critical.
- In vivo editing and delivery: In vivo HSPC editing or non–double-strand break technologies (base or prime editing) could simplify logistics, reduce manufacturing failures, and potentially improve safety profiles.
- Comparative effectiveness: Head-to-head or well-designed indirect comparisons across gene therapies (enhancer editing versus transgene addition) and against allogeneic transplantation would inform optimal patient selection, sequencing, and payer decisions.
- Biomarkers and endpoints: Harmonized definitions of VOCs, digital pain monitoring, and standardized assays for HbF pancellularity and clonal tracking will enhance comparability across studies and real-world registries.
- Access and equity: Streamlined manufacturing, decentralized care pathways, and global capacity-building are needed to deliver these curative-intent therapies to the populations most affected by SCD. Cost-effectiveness analyses and value-based payment models will be integral to equitable adoption.

Conclusions
- This study demonstrates that ex vivo CRISPR-Cas9 editing of the BCL11A erythroid enhancer in autologous HSPCs produces robust, durable HbF reactivation with pancellular distribution, translating into substantial reductions in VOCs and improvements in hemolysis and patient-reported outcomes. The efficacy and early safety profile are consistent with the therapeutic class exemplified by Casgevy and compare favorably with outcomes reported for Lyfgenia, while differing in mechanisms and long-term risk considerations.
- The principal risks observed to date reflect myeloablative conditioning; no signals of clonal dominance or hematologic malignancy have emerged, but long-term follow-up is essential to confirm genomic safety and durability. If these favorable trends persist, this therapy has the potential to offer a transformative, one-time treatment option for individuals with severe SCD, reducing lifetime morbidity and healthcare utilization.
- Realizing this potential will depend on continued accrual of long-term data, optimization of conditioning, expansion to earlier disease stages, and concerted efforts to ensure access. Pending these developments, the benefit–risk profile appears favorable for appropriately selected patients, supporting further clinical development and broader implementation in specialized centers.